Sartorius from Göttingen: Sales and profits rise sharply in the first half of the year!

Sartorius from Göttingen: Sales and profits rise sharply in the first half of the year!

A small ray of hope in difficult times: Sartorius, the renowned laboratory and pharmaceutical supplier from Göttingen, is in impressive shape in the first half of 2025. Amid challenging global conditions, the company managed to record both sales and profit growth. The current figures speak for themselves: Compared to the previous year, sales climbed by around six percent to an impressive 1.77 billion euros (adjusted for exchange rates) and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) almost doubled to 527 million euros. Net profit after third-party shares also increased significantly and reached 81 million euros, which corresponds to an increase of a third compared to the previous year.[Sat1 Regional reports]

The new CEO Michael Grosse is optimistic and sees Sartorius on the right track to achieving its annual targets. Despite falling demand over the last two years, the company has streamlined its internal structure through a savings program worth over 100 million euros, completed at the end of 2024. Nevertheless, the environment remains challenging: customers are holding back on new investments as they continue to reduce high inventories that they built up during the Corona pandemic.

Stability and stimulation

According to internal reports from Sartorius, the situation stabilized in 2024. This stability comes in a challenging life sciences environment where demand for products and services is not always easy to predict. What is particularly noteworthy is the significant recovery that was observed in the second half of the year, especially in the final quarter.[ir-reports.sartorius.com]

A positive trend reversal is particularly evident in the consumables business, where customers have gradually reached their downwardly revised target inventory levels. Step by step, companies are returning to order levels that reflect actual production activity. There are even above-average developments in the area of ​​novel therapies, which further stimulates the order situation.

Growth of the workforce

There is also good news from the human resources department: Sartorius has increased its workforce to 13,685 employees, which represents a slight increase of 157 employees compared to the end of 2024. What is particularly noteworthy is that these increases are in manufacturing, which is a good indication of the company's continued growth and shows that Sartorius has a good hand at overcoming the challenges of the industry.

All in all, Sartorius is doing well despite the many hurdles. With a solid foundation and a positive outlook for the next few months, the company remains in the conversation and on the radar of investors and industry experts.